A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis

Publication date: Oct 10, 2019

A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

Concepts Keywords
Creatinine Renal function
Creatinine Clearance Chemistry
Demyelination Creatinine
Electrophysiological RTT
Gender Metformin
Glomerular Filtration Rate Branches of biology
Immunomodulatory Biguanides
Liver Guanidines
Metformin Renal physiology
Mol
Multiple Sclerosis
Neuropsychological Testing
Organ
Radioisotope
Relapse
Renal
Visual Pathway

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
gene UNIPROT RAPGEF5
drug DRUGBANK Creatinine
disease MESH abnormalities
disease MESH renal
gene UNIPROT PLXNA2
disease MESH demyelination
gene UNIPROT RENBP
disease MESH relapse
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
drug DRUGBANK Metformin

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *